|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conclude that the decreased expression of the tumor-suppressive miR-23b/27b cluster enhanced cancer cell proliferation, migration and invasion in BC through direct regulation of EGFR and c-Met signaling pathways.
|
25405368 |
2015 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SH3BGRL3 expression is significantly associated with a high level of epidermal growth factor receptor (EGFR) in bladder cancer (P < 0.0001).
|
26286913 |
2015 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings provide preclinical proof of concept that anti-EGFR therapy can be used to target a subset of particularly aggressive MIBC tumors expressing basal cell markers and provide diagnostic tools for identifying these tumors.
|
25009231 |
2014 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In these cell lines, DIM-C significantly sensitized bladder cancer cell lines that were resistant to EGFR inhibition in a schedule-specific manner.
|
23409107 |
2013 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggested that EGFR 3'UTR 774T>C polymorphism may contribute to susceptibility to bladder cancer.
|
23028094 |
2013 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
CXCR7 promotes BCa cell proliferation and motility plausibly through epidermal growth factor receptor receptor and Akt signaling.
|
22736438 |
2013 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ErbB receptor tyrosine kinase family expression levels in urothelial bladder carcinoma.
|
23333248 |
2013 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first evidence was provided that miR-133a and miR-133b may directly target the epidermal growth factor receptor in bladder cancer.
|
23206218 |
2013 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings provide us with an insight into LRIG1 function, and we conclude that LRIG1 evolved in bladder cancer as a rare feedback negative attenuator of EGFR, thus could offer a novel therapeutic target to treat patients with bladder cancer.
|
24314030 |
2013 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study analyzes the immunoexpression of EGFR and Her2/neu in 45 cases of papillary urothelial bladder carcinoma.
|
23529321 |
2013 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Haplotype analysis further revealed three haplotypes within VEGFC and two haplotypes in EGFR were significantly associated with increased bladder cancer risk compared to the most common haplotype.
|
23251617 |
2012 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we tested the consequences of STAT3 inhibition in EGFR inhibitor-resistant head and neck squamous cell carcinoma (HNSCC) and bladder cancer models to determine whether STAT3 blockade can enhance responses to EGFR targeting.
|
22825581 |
2012 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In epidermal growth factor receptor expressing bladder cancer co-expression of platelet-derived growth factor receptor-β has implications for tumor biology.
|
21168861 |
2011 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous in vitro studies demonstrated that leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1), a negative regulator of EGFR, is a novel agent for suppressing bladder cancer.
|
21567105 |
2011 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In AR-positive bladder cancer UMUC3 and TCC-SUP cells, dihydrotestosterone (DHT) increased the expression of EGFR and ERBB2 both in mRNA and in protein levels, and an anti-androgen hydroxyflutamide antagonized the effect of DHT.
|
21613411 |
2011 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There is a wide spectrum of NRG1 and ERBB receptor expression in bladder cancer.
|
21364580 |
2011 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results show that EGFR is an Sp-regulated gene in bladder cancer, and drugs such as BA and curcumin that repress Sp proteins also ablate EGFR expression.
|
20407012 |
2010 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest modified bladder cancer risk and survival associated with genetic variation in the EGFR pathway.
|
19372140 |
2009 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to establish an orthotopic human bladder carcinoma mouse model using the epidermal growth factor receptor (EGFR)-overexpressing bladder carcinoma cell line EJ28 and to compare therapeutic efficacy of intravesically instilled alpha-particle-emitting (213)Bi-anti-EGFR-monoclonal antibody (mAb) with mitomycin C.
|
19793735 |
2009 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.
|
19881954 |
2009 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.
|
19671845 |
2009 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the anti-tumor effects of PDT plus Erbitux, an angiogenesis inhibitor that targets epidermal growth factor receptor (EGFR), on human bladder cancer model.
|
19878607 |
2009 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cell-surface HER1/EGFR expression was present in all seven bladder cancer cell lines.
|
17346275 |
2007 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The kinase domain of EGFR (exons 18-21) from 11 bladder cancer cell lines as well as from 75 patient tumors was analyzed by automated sequencing.
|
17690890 |
2007 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib.
|
17707060 |
2007 |